ArticleBMC cancer2026
Clinical and imaging characteristics of phosphaturic mesenchymal tumors: a case series analysis.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo characterize the clinical, biochemical, pathological, and multimodal imaging features of phosphaturic mesenchymal tumors (PMTs).
methodsWe retrospectively reviewed 10 patients with pathologically confirmed PMT. Clinical presentation, laboratory findings, histopathologic and immunohistochemical features, and imaging manifestations across multiple modalities were systematically analyzed.
resultsAll patients presented with long-standing fatigue and bone pain. Preoperative laboratory tests revealed varying degrees of hypophosphatemia and elevated alkaline phosphatase, while postoperative serum phosphate levels gradually normalized. Histopathology demonstrated heterogeneous morphologies. Immunohistochemistry showed consistent SATB2 and SSTR2 positivity in tested cases, whereas the Ki-67 proliferation index ranged from 1% to 15%. On CT, primary lesions appeared as soft-tissue density masses or ground-glass-like nodules, often with irregular calcification and focal bone destruction. MRI demonstrated hypointensity on T1-weighted images, hyperintensity on T2-weighted images, and moderate to marked heterogeneous enhancement. Both [
conclusionPMTs are characterized by typical TIO-related clinical and biochemical abnormalities, and SATB2 and SSTR2 are highly sensitive immunohistochemical markers for definitive diagnosis. Whole-body [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.